What is the value of antibiotics? And how should we pay for them?

Thursday 16 May 2019, 12.15PM to - 1.15pm

Speaker(s): Dr Itamar Megiddo, University of Strathclyde

Abstract: The existing business models for antibiotics fail to promote antibiotics stewardship to preserve our existing portfolio of drugs, while at the same time funding for research and development has been insufficient in recent decades. Only two novel classes of antibiotics have been introduced since the 1970s. A number of groups (e.g., DRIVE-AB and EEPRU) have discussed how antibiotics differ from other health technologies and have developed conceptual frameworks for valuing them.

We explore two models for valuing antibiotics. First, we explore the option value of preserving an antibiotic for an extreme event. We consider an example of secondary bacterial infections during pandemic influenza. Second, we present a “delinked” model — removing the link between reimbursement for use and sales — that the UK government is testing. We study these models to understand how to value antibiotics, what the structure of the fixed and volume-based payments in the delinked model should look like, and how we may be able to use expert judgment to support the model.

Location: Alcuin A Block A019/20

Who to contact

For more information on these seminars, contact:

Thomas Patton
Dina Jankovic

Economic evaluation seminar dates

  • Thursday 13 June
    Dr Hayley Jones, University of Bristol
  • Thursday 20 June
    Dr Rhiannon Owen, University of Leicester
  • Thursday 19 September
    Dr Howard Thom, University of Bristol
  • Thursday 10 October
    Dr Laura Bojke, CHE, University of York
  • Thursday 14 November
    Sofia Dias, CRD, University of York